SCHEMBL4357501

SCHEMBL4357501

NC(=O)c1cc(NC(=O)NCCc2ccccc2)cc(Cl)c1O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 5/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
NPC1 O15118 3/20 0.57
RAB9A P51151 3/20 0.57
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
MAPT P10636 3/20 0.57
EPHX1 P07099 2/20 0.51
HDAC1 Q13547 2/20 0.51
HDAC2 Q92769 2/20 0.51
CA2 P00918 5/20 0.50
CA1 P00915 4/20 0.50
CA12 O43570 3/20 0.50
CA9 Q16790 3/20 0.50
LMNA P02545 3/20 0.49
HTT P42858 2/20 0.49
ALDH1A1 P00352 1/20 0.49
TP53 P04637 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4351106 0.89 CNR1 (0.68) CNR1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL4357505 0.85 CNR1 (0.60) CNR1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL4351546 0.83 MAPT (0.55) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL6568451 0.81 KDM4E (0.69) CNR1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL4349474 0.79 EPHX1 (0.58) CNR1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL4341839 0.79 CNR1 (0.68) CNR1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL8120676 0.78 HDAC1 (0.62) CNR1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL6568654 0.78 CNR1 (0.60) CNR1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL19472703 0.77 MAPT (0.58) CNR1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL6250660 0.77 CNR1 (0.52) CNR1SMN1; SMN2NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
EP-1539683-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS Jerini AG (DE) 2005-06-15 EP claimed
WO-2004030664-A2 NEW COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF JERINI AG (DE) 2004-04-15 WO claimed
WO-2004026815-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS JERINI AG (DE) 2004-04-01 WO claimed
EP-1402887-A1 New compounds for the inhibition of undesired cell proliferation and use thereof Jerini AG (DE) 2004-03-31 EP claimed
EP-1402888-A1 The use of substituted carbocyclic compounds as rotamases inhibitors Jerini AG (DE) 2004-03-31 EP claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 CNR1 120/4885SMN1; SMN2 1791/4885NPC1 815/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 CNR1 175/4885SMN1; SMN2 3250/4885NPC1 1189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.